HUTCHMED stock fell 2.54 percent as H1 revenue reached USD 278 million

Published on 10/04/2026 at 19:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

HUTCHMED stock posted USD 162 million in oncology revenue in H1 2026, up 23 percent year over year. Full-year guidance remained USD 330 million to USD 450 million.

HCM, US44842L1035, Illustration mit AI erstellt.

HUTCHMED (China) stock (ISIN US44842L1035) fell 2.54 percent to USD 14.20 on Nasdaq on October 2, 2026, after the company reported USD 278 million in first-half 2026 revenue. The latest figures show a split picture: oncology revenue rose 23 percent to USD 162 million, while the broader earnings profile remains tied to pipeline investment and regulatory progress.

Oncology revenue reaches USD 162 million

According to ScanX News on September 18, 2026, HUTCHMED generated USD 162 million in oncology revenue during the first half of 2026, a 23 percent year-over-year increase. Total group revenue reached USD 278 million, while research and development expenses rose to USD 79 million from USD 72 million in the comparable period.

The company retained full-year revenue guidance of USD 330 million to USD 450 million, according to ScanX News. Ex-US FRUZAQLA sales rose 70 percent in the first half, and China product sales grew more than 40 percent, providing the main operating contrast to the lower group-level earnings contribution.

FDA filing adds a pipeline checkpoint

On September 28, 2026, AstraZeneca submitted a New Drug Application to the US Food and Drug Administration for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated non-small cell lung cancer, as Markets Insider reported. The SAFFRON Phase III trial supporting the application enrolled 338 patients and showed statistically significant improvements in progression-free and overall survival versus doublet platinum-based chemotherapy.

The FDA filing adds a regulatory milestone to HUTCHMED's commercial oncology base, but it does not represent an approval. The company also scheduled presentations of new and updated clinical data at the ESMO Congress beginning October 23, 2026, according to MarketScreener.

Consensus stays close to Nasdaq price

Market expectations remain measured. MarketBeat reported a Hold consensus from seven analysts on September 18, 2026, with two Sell ratings, one Hold, three Buy ratings and one Strong Buy. The average 12-month price target was USD 14.87, which stood 4.7 percent above the October 2 Nasdaq price of USD 14.20.

HUTCHMED stock stays below yearly high

HUTCHMED stock was last at USD 14.20 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down USD 0.37 from the prior close. The price stood 13.4 percent below its 52-week high of USD 16.40 and above the 52-week low of USD 9.77.